ATM-like machines hope to give a boost to generics sampling, WSJ reports

Share this article:
In an initiative to trim spending, insurers are planning to put ATM-style machines dispensing free generic drug samples in doctors' offices around the country, The Wall Street Journal reported today.
Insurer Aetna plans to unveil a pilot program in which it wants to place the machines with doctors around Philadelphia in advance of a national rollout representing the largest use of the ATM-generic strategy to date.
The dispensing machines aim to provide a counterweight to samples of branded drugs distributed for free by sales reps working for pharmaceutical companies.
Last year, doctors received more than one billion branded drug samples – more than three for every person in the U.S. – valued at nearly $16 billion, according to IMS Health data.
The generic machines will, in most cases, dispense a 30-day supply of medication, offering an advantage over branded samples, which often last only a week or so.
"We're saving patients money," Jeff Taylor, director of pharmacy for Aetna, told The Journal.
Aetna said that for common infections the machines would provide a free sample adequate to treat the condition – meaning the patient's drug cost would be zero.
Neither Aetna nor the maker of the machines, MedVantx, is offering payment or other inducements to doctors who agree to accept the machines in their offices.
Financial terms of the relationship between MedVantx and Aetna have not been disclosed. MedVantx, not Aetna, owns the equipment and provides the packets inside. Aetna pays MedVantx for the drugs dispensed, plus a processing fee.
In the past two years, MedVantx machines installed at more than 100 doctors' offices have dispensed more than 111,000 samples.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...